BenzingaSeptember 3, 2026 at 12:06 AM NYyesterday

Biogen And Eisai Win China Approval For At-Home Weekly Leqembi Alzheimer’s Treatment

Eisai Co., Ltd. and Biogen Inc. (NASDAQ:BIIB) announced today that the National Medical Products Administration (NMPA) of China has approved the subcutaneous formulation (subcutaneous autoinjector: SC-AI), the

Read the Full Story at the Source

The summary here comes from the news provider; the rest of the article lives on the publisher's site — Benzinga

Read at Source

Companies in This Story

BIIBBiogen Inc220.83− 1.64%

Companies in This Story

Related Stories